Navigation Links
Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up!
Date:12/20/2007

NEW YORK, Aug. 10 /PRNewswire/ -- ExL Pharma is pleased to announce the fall conference line up which covers many of the leading issues that are impacting the pharmaceutical industry today. The events that are currently scheduled offer educational and networking opportunities for Clinical, Marketing, R&D, and Medical Affairs executives from large to small pharmaceutical, biotech and medical technology companies.

Listed below are details on some of the featured events and highlights from those conferences:

September 10-11th, Philadelphia, PA

3rd Clinical Performance Metrics & Benchmarking- Measuring and Improving

Clinical Performance to Maximize Efficiency

The 2007 Metrics event features 5 Case Study examples from Pfizer, Merck,

Allergan, Astrazeneca, and Sanofi-Aventis on different clinical

performance measurement applications.

September 13-14th, San Francisco, CA

6th Investigator-Initiated Trials- Ensuring Quality Studies through

Increased Collaboration,

Participate in the first ever IIT working group and help shape best

practices and form future guidelines.

September 24-25th, Annapolis, MD

3rd Merging EHR & eClinical Technologies- Implementing the Technology for

Convergence

This event features presentations from Pfizer, Allscripts, Johnson &

Johnson, HL7 and CDISC discussing strategies for integrating drug

development and healthcare IT.

October 22-24, Princeton, NJ

Digital Pharma- Accelerating to the Next Generation of Marketing with Web

2.0

Hear leading pharmaceutical companies such as Abbott, Wyeth and Bayer

discuss how they are taking full advantage of Web 2.0 marketing strategies

to communicate with consumers and physicians.

November 5-6th, Princeton, NJ

3rd Pharmaceutical Meeting Planners Summit- The Ideal Networking

Environment for Pharmaceutical Meeting Planners

This newly updated
'/>"/>

SOURCE ExL Pharma
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
2. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
5. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
6. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
7. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
8. AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
11. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Md., Nov. 20 Novavax, In...iced an underwritten public offering of 6,800,000 ...c of $3.30 per share. The approximately $21 milli...ng discounts and commissions, will be used for pre...sed vaccines, internal research and development pr...
(Date:11/20/2009)... METTLER TOLEDO recently announced that Dr. Domin...The Role of Process Analytical Technology (PAT) in...ecember 1, 2009. , (PRWEB...cess Analytical Technology (PAT) in Green Chemistr...ocess Analytical Technology (PAT) case studies wil...
(Date:11/19/2009)...., Nov. 19 Dr. Mate Hidvegi, inven...ds to a press release issued on November 17 by Bir...r making false and self-serving statements about i.... Hidvegi stated from his office in Budapest, Hung... Avemar does not apply to AveULTRA, www.aveultra...
(Date:11/19/2009)...Pa. and WALTHAM, Mass., Nov. 19 Ar...rces find that the leading driver of antibiotic se...-spectrum activity against gram-positive and gram-...s that can cause nosocomial pneumonia, surveyed Eu...for agents that provide appropriate coverage again...
Breaking Biology Technology:Novavax Prices Public Offering of Common Stock 2Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...ovides supplemental recognition factor to assist i...on, INDIANAPOLIS, Oct. 27 Eli Lilly and Company,...a color differentiation,system for U-100 insulin p...ials, pens and individual packaging for Humalog(R)...lin(R) (regular insulin human injection,USP [rDNA ...
...ATTLE, Oct. 27 Trubion Pharmaceuticals Inc.,(Nasd...hase 1/2a study,demonstrating that repeat administ...t responses and significant improvements in rheuma...erican College of Rheumatology (ACR),criteria. Tru...liminary,analyses from a Phase 2b study in which p...
...nagement to Host Conference Call at 8:30 a.m. East...ss Results, BIRMINGHAM, Ala., Oct. 27 BioCryst,P...ced results of an,exploratory Phase 2 trial of int...or, in patients hospitalized for acute serious or ...2 trial compared the efficacy and,safety of five d...
Other Biology Technology:Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 2Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 3Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 4Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 5Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
(Date:11/20/2009)... estimated 4.6 million Americans involved in the e...atory symptoms due to poor air quality in horse ba... earlier this year by investigators at Tufts Unive... The studywhich polled more than 80 New England h...als working in barns complained of coughing, wheez...
(Date:11/20/2009)...shives, and generated from Brassica carinata , a ...f fields in spring, can be used to produce bioetha...d out by Spanish and Dutch researchers and publish...y Reviews . , "These studies evaluate, from an en...hanol from two, as yet unexploited sources of biom...
(Date:11/19/2009)...d of the last ice age, North America,s vast assemb...ures as mammoths, mastodons, camels, horses, groun...s slide to extinction. , And when their populati...rge animals equaled or surpassed Africa,s wildlife...vel ecosystem emerged as broadleaved trees once ke...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Flax and yellow flowers can produce bioethanol 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Ten Professional Societies Join Forces to Develop Obesity Medicine Certification Examination 53683 1Ten Professional Societies Join Forces to Develop Obesity Medicine Certification Examination 53683 2Neuropathic pain 3A The sea provides a new hope of relief 9475 1Neuropathic pain 3A The sea provides a new hope of relief 9475 2Demi Lovato Joins National Bullying Prevention Movement 53681 1Demi Lovato Joins National Bullying Prevention Movement 53681 2
...gists at Washington University in St. Louis shows ...rea, the less chance humans have of exposure to We...birds. , "The bottom line is that where there are ...lower risk of contracting West Nile Fever," said B...& Sciences at Washington University in St. Louis. ...
...James D. Rives Professor of Surgery and Neuroscien...ol of Medicine, and Dr. Conrad Hornick, former LSU...S Patent for a compound to inhibit the formation o...s tumors and diseases like diabetic retinopathy, o...e major protein component of lipoproteins water so...
...sing nanotechnology to search for new cancer-fight...,000 times faster than current methods. , The "La...ls simultaneously using tiny plastic beads so smal.... Each bead carries a separate chemical, which ca...s needed to treat cancer cells. One batch of nano...
Other Biology News:Study: Bird diversity lessens human exposure to West Nile Virus 2LSUHSC awarded patent for compound inhibiting cancer and other diseases 2Nanoscopic screening process to speed drug discovery 2
Goat Anti-SMAD7, MADH7 Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human PRG3 Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-C3a / C3a des Arg Monoclonal Antibody, Unconjugated, Clone 2991 from Abcam
Mouse Anti-DNA-PKcs, phospho (Thr2609) Monoclonal Antibody, Unconjugated, Clone 10B1 from BioLegend
Biology Products: